Aspen generic semaglutide has been approved in Brazil and South Africa, Africa’s largest drugmaker said on 11 November 2026, putting the company among the first generic entrants in two big emerging markets opened up by the expiry of Novo Nordisk’s semaglutide patents. Commercial launches are expected within the next few months, prices will sit below Ozempic and Wegovy, and the injection will initially be manufactured in India before production moves to Aspen’s own sterile plants in South Africa and France.
For Indian readers the story has a direct link home: India was the first major market to see a wave of semaglutide generics in March 2026, and Indian manufacturing capacity is now feeding launches abroad. Here is what Aspen has, and has not, disclosed, and how it compares with what Indian patients already pay.
Key takeaways on Aspen generic semaglutide
- Regulators in Brazil and South Africa approved Aspen’s generic injectable semaglutide; Canada approved it in July 2026.
- In South Africa the approved use is type 2 diabetes in adults. Doctors may prescribe it off-label for weight management.
- Aspen has not published a price but says it will undercut Novo Nordisk’s Ozempic and Wegovy.
- Initial supply will come from India, with later production in South Africa and France.
- Aspen is seeking registration in about 20 more countries and expects a crowded generic field.
What the approvals cover
The South African registration, issued by the South African Health Products Regulatory Authority (SAHPRA), is for adults with type 2 diabetes, the same use as Ozempic. That matters because many people searching for semaglutide want it for weight loss, the use covered by Wegovy at a higher dose. A diabetes label does not stop a doctor prescribing off-label, but it does shape pricing, insurance cover and how the product can be marketed. Aspen did not detail the Brazilian label in its public comments.
Aspen will not be alone. SAHPRA approved a Ranbaxy generic, branded Semagard, in July and Novo Nordisk’s own second brand, Semditu, in October. In July the regulator said it had 12 generic semaglutide applications under review. We covered the related regulatory pressure on compounded products in our report on South Africa’s GLP-1 compounding crackdown.
Where Aspen sits in the semaglutide generic race
| Market | Status of generic semaglutide | Notable players |
|---|---|---|
| India | Generics launched 21 March 2026 after core patent expiry | Dr. Reddy’s, Zydus, Lupin, Alkem, Sun Pharma, Glenmark |
| Canada | Aspen approved July 2026 | Aspen and other filers |
| South Africa | Semagard (Jul), Semditu (Oct), Aspen (Nov); 12 applications reviewed | Ranbaxy, Novo Nordisk, Aspen |
| Brazil | Aspen approved Nov 2026 | Aspen |
The India connection
Aspen’s decision to source its first batches from India reflects how quickly Indian makers built capacity for this peptide. When the core Indian patent lapsed in March, at least six domestic companies launched brands on day one, with reported launch prices that ranged from about Rs 1,800 a month for Alkem’s lowest-priced pen to about Rs 4,200 a month for Dr. Reddy’s Obeda. Those prices are a fraction of the branded products and give a rough guide to the level emerging markets may reach once several generics compete.
The flip side is that Indian contract and API makers now face a test of quality at scale. Semaglutide is a complex peptide delivered by pen injector, and regulators in export markets will be watching consistency closely. Dr. Reddy’s recent FDA tentative approval for generic lenacapavir shows Indian firms are increasingly first to file on high-profile molecules.
Will it hurt Mounjaro or Novo Nordisk?
Aspen also markets Eli Lilly’s Mounjaro (tirzepatide) in South Africa and other sub-Saharan countries, so it is in the unusual position of selling both a branded dual-hormone drug and a cheaper single-hormone generic. Chief financial officer Sean Capazorio said he does not expect the generic to cannibalise Mounjaro, which helped lift Aspen’s normalised headline earnings per share by 22% in the year to 30 June. Chief executive Stephen Saad told reporters, “I’ve never seen a category grow like this.”
For Novo Nordisk, the bigger threat is volume rather than any single competitor. Its launch of a second-brand semaglutide in South Africa suggests it intends to compete on price rather than cede the market. Aspen says lower prices should expand total use, but it also expects margins to come under pressure as more filers win approval.
Market context
Acumen Research and Consulting valued the global anti-obesity drugs market at USD 2.1 billion in 2022 and forecast USD 8.2 billion by 2032, growth of 14.6% a year, with Asia-Pacific the fastest-growing region and prescription drugs the dominant segment. The report was last updated in September 2023, before generic semaglutide reached the market, so these figures are best read as indicative. Off-label weight-loss use of diabetes-labelled generics like Aspen’s could push real-world demand well beyond the obesity segment as defined there.
What patients should know
- Approval does not mean the product is in pharmacies yet; Aspen expects launches in the coming months.
- Generic semaglutide is a prescription medicine. Use it only under a doctor’s supervision, as GI side effects and rare serious risks apply.
- Buy only approved, registered products through licensed pharmacies, not unregulated online sellers.
More approval news is in our Drug Approvals section.
FAQ
Is Aspen’s generic semaglutide the same as Ozempic?
It contains the same active ingredient, semaglutide, and in South Africa is approved for the same use, type 2 diabetes in adults. Regulators approve generics after reviewing evidence that they match the reference product.
When will Aspen semaglutide be available in South Africa and Brazil?
Aspen says commercial launches are expected within the next few months. It has not given a specific date.
How much will Aspen generic semaglutide cost?
Aspen has not disclosed pricing, only that it will be cheaper than Ozempic and Wegovy.
Is generic semaglutide available in India?
Yes. Several Indian companies launched generic semaglutide in March 2026 after the core patent expired, at prices reported from about Rs 1,800 a month.
Sources: Aspen Pharmacare JSE SENS announcement and company comments (11 Nov 2026) as reported by Reuters, TimesLIVE and MedicalBrief; SAHPRA announcements; India launch reports (Mar 2026). Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated 12 November 2026.

[…] Novo to First Oral GLP-1 Nod CAR-T for Lupus: Why Patients Still Line Up After Four Trial Deaths Aspen Generic Semaglutide Wins Brazil and South Africa Approval, Made in India First Temple Wearable: Why Doctors Doubt Deepinder Goyal’s BrainFlow Claim Brelovitug Wins […]
[…] to semaglutide is widening as Indian manufacturers produce lower-cost versions, including the made-in-India generic semaglutide now approved abroad. The review’s message for doctors and patients is to prescribe these drugs for their proven […]
[…] is starting to reach markets such as Brazil and South Africa, as we reported in our coverage of Aspen’s generic semaglutide approvals. A differentiated, long-acting branded option gives distributors like Arcera something to sell that […]
[…] Access to semaglutide is widening as Indian manufacturers move into the category, as seen with the first India-made generic semaglutide approvals abroad. If heart benefits beyond weight loss are confirmed, cardiologists could gain a stronger case for […]